Phosphorylated PEG Suppresses Pseudomonas Virulence

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Anastomotic leaks remain a significant complication in gastrointestinal surgery, despite advances in technique and technology, due to the transformation of microbial pathogens like Pseudomonas aeruginosa into a tissue-destructive phenotype at the site of tissue injury, leading to bowel dysfunction, cancer recurrence, and sepsis-related deaths, with the underlying mechanism not fully understood.

Innovation Solution

The use of high molecular weight polyethylene glycol (PEG) with added phosphate, specifically phosphorylated PEG, is administered to suppress the virulence of Pseudomonas aeruginosa by preventing its transformation into a tissue-destructive phenotype, thereby preventing anastomotic leaks by inhibiting its swarming capacity and collagenase activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are administered to prevent anastomotic leaks, then microbial infection is reduced, but the underlying mechanism of leak development remains unaddressed and surgical technique improvements are insufficient

Engineering Contradiction:

Improveanastomotic healingVSAvoidsurgical technique

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces PEG phosphate as an intermediary substance that mediates between the surgical anastomosis and the microbial environment. This compound specifically targets and suppresses the virulence transformation of P. aeruginosa without requiring complex surgical modifications, thereby improving anastomotic healing reliability through a biochemical intermediary rather than through increasingly complex surgical techniques.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the chemical parameter of the local environment by introducing PEG phosphate, which alters the molecular weight and chemical composition parameters of the substance present at the anastomosis site. This parameter change specifically suppresses bacterial virulence transformation, addressing the reliability issue without increasing surgical technique complexity.

Inventive Principle:

Principle #35Parameter changes

2Object-generated harmful factors

If Pseudomonas aeruginosa transforms into tissue-destructive phenotype at the anastomosis site, then microbial virulence increases, but standard antibiotic treatment fails to prevent this transformation

Engineering Contradiction:

Improvemicrobial virulenceVSAvoidanastomotic integrity

Core Design Contradiction:

Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent applies preliminary anti-action by administering PEG phosphate before the bacterial virulence transformation can occur. This compound preemptively suppresses the transformation of P. aeruginosa into its tissue-destructive phenotype, preventing the generation of harmful factors rather than treating them after they appear, thereby maintaining anastomotic integrity.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent converts the harmful presence of P. aeruginosa into a beneficial outcome by using PEG phosphate to specifically suppress its virulence transformation. The bacteria remain present but are prevented from becoming tissue-destructive, thereby converting a potentially harmful situation into a benign one that maintains anastomotic integrity.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Ease of operation

If conventional surgical techniques are used, then surgical procedure simplicity is maintained, but anastomotic leaks occur due to unaddressed microbial transformation

Engineering Contradiction:

Improvesurgical procedureVSAvoidanastomotic leak prevention

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent segments the problem-solving approach by separating the surgical component from the biochemical component. The surgical procedure remains simple and unchanged, while a separate biochemical intervention (PEG phosphate administration) addresses the microbial transformation issue, thereby maintaining ease of operation while improving leak prevention reliability.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces PEG phosphate as an intermediary that bridges the gap between simple surgical technique and improved healing outcomes. This mediator substance handles the complex microbial interaction problem, allowing the surgical procedure itself to remain simple and easy to perform while still achieving better reliability through the intermediary's biochemical actions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS9937199B2Materials and methods for preventing and treating anastomotic leaks

Publication Date: 2018.04.10 UNIVERSITY OF CHICAGO

AI summary

Materials and methods for preventing and treating anastomotic leaks are disclosed. Data establishes that pathogenic microbes interfere with establishing epithelial cell barriers in anastomoses and, more generally, with the reconnection of any two portions of like or different tissues comprising epithelia. Suitable prophylactic and therapeutic composition comprise, e.g., a phosphorylated high molecular weight polyethylene glycol compound.